{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T05:06:18Z","timestamp":1784264778083,"version":"3.55.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the clinical efficacy and safety of CalliSpheres drug-eluting bead transarterial chemoembolization (DEB-TACE) in patients with unresectable gastrointestinal stromal tumor (GIST) liver metastases after the failure of targeted therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>77 patients with unresectable GIST liver metastases who had failed at least two lines of targeted therapy were retrospectively enrolled from three centers between January 2022 to December 2024. Based on their treatment regimen, patients were divided into an observation group (n=34) and a control group (n=43). The control group continued receiving tyrosine kinase inhibitors (TKIs) or best supportive care (BSC). The observation group underwent DEB-TACE followed by TKI therapy or BSC. Tumor response was assessed using the modified Response Evaluation Criteria in Solid Tumors (mRECIST). Overall survival (OS), progression-free survival (PFS), and adverse events during treatment were recorded and analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At the first efficacy evaluation, the observation group exhibited an objective response rate (ORR) of 94.12% (10 complete response [CR], 22 partial response [PR]) and a disease control rate (DCR) of 100%. In the control group, the ORR was 4.65% (2 PR) and the DCR was 39.53%. The median PFS (liver) was significantly longer in the observation group (11.0 months) than in the control group (5.0 months; P &amp;lt; 0.001). The median OS was also longer in the observation group (18.0 months vs. 12.0 months; P &amp;lt; 0.001). Prognostic analysis indicated that better baseline liver function, fewer prior lines of therapy, and DEB-TACE treatment were associated with improved outcomes. Adverse events in the observation group were primarily related to post-embolization syndrome and transient liver injury, with no increase in targeted therapy-related toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>DEB-TACE demonstrates favorable efficacy and a manageable safety profile in patients with unresectable GIST liver metastases after targeted therapy failure, representing a safe and feasible treatment option worthy of clinical application.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1784905","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T04:24:05Z","timestamp":1784262245000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of CalliSpheres drug-eluting bead transarterial chemoembolization for unresectable gastrointestinal stromal tumor liver metastases after failure of targeted therapy: a multicenter retrospective study"],"prefix":"10.3389","volume":"16","author":[{"given":"Song","family":"Liu","sequence":"first","affiliation":[{"name":"Cancer Interventional Center, Linyi Cancer Hospital","place":["Linyi, Shandong, China"]},{"name":"Dalian Medical University","place":["Dalian, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Chen","sequence":"additional","affiliation":[{"name":"General Surgery Department, Linyi Cancer Hospital","place":["Linyi, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunhang","family":"Yin","sequence":"additional","affiliation":[{"name":"Cancer Interventional Center\/Minimally invasive Tumor Interventional Center, Affiliated Zhongshan Hospital of Dalian University","place":["Dalian, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangji","family":"Yu","sequence":"additional","affiliation":[{"name":"Cancer Interventional Center, Linyi Cancer Hospital","place":["Linyi, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingdong","family":"Wang","sequence":"additional","affiliation":[{"name":"Cancer Interventional Center, Linyi Cancer Hospital","place":["Linyi, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Li","sequence":"additional","affiliation":[{"name":"Cancer Interventional Center, Linyi Cancer Hospital","place":["Linyi, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangsheng","family":"Zhao","sequence":"additional","affiliation":[{"name":"Cancer Interventional Center\/Minimally invasive Tumor Interventional Center, Affiliated Zhongshan Hospital of Dalian University","place":["Dalian, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Anorectal Surgery, Affiliated Zhongshan Hospital of Dalian University","place":["Dalian, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Buqiang","family":"Zhuang","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, The Affiliated Hospital of Xuzhou Medical University","place":["Xuzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/MOG.0000000000000584","article-title":"Gastrointestinal stromal tumor: epidemiology, diagnosis, and treatment","volume":"35","author":"Mantese","year":"2019","journal-title":"Curr Opin Gastroenterol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-200001000-00008","article-title":"Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival","volume":"231","author":"DeMatteo","year":"2000","journal-title":"Ann Surg"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-019-02094-y","article-title":"Metastatic pattern and prognosis of gastrointestinal stromal tumor (GIST): a SEER-based analysis","volume":"21","author":"Yang","year":"2019","journal-title":"Clin Transl Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00606-4","article-title":"New treatment strategies for advanced-stage gastrointestinal stromal tumours","volume":"19","author":"Klug","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/cai2.70027","article-title":"Yttrium-90 selective internal radiotherapy for gastrointestinal stromal tumor with liver metastasis: a case report and review","volume":"4","author":"Xing","year":"2025","journal-title":"Cancer Innov"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0b013e31819cca35","article-title":"Hepatic arterial embolization and chemoembolization for imatinib-resistant gastrointestinal stromal tumors","volume":"32","author":"Kobayashi","year":"2009","journal-title":"Am J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1526268","article-title":"Drug-eluting beads transarterial chemoembolization vs conventional transarterial chemoembolization in the treatment of hepatocellular carcinoma in adult patients: a systematic review and update meta-analysis of observational studies","volume":"14","author":"Chernyshenko","year":"2025","journal-title":"Front Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2024.2390025","article-title":"Efficacy of CalliSpheres\u00ae drug-loaded microspheres combined with doxorubicin in hepatocellular carcinoma","volume":"59","author":"Jin","year":"2024","journal-title":"Scand J Gastroenterol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.05.535","article-title":"Twenty-year survival of advanced gastrointestinal stromal tumours treated with imatinib: exploratory long-term follow-up of the BFR14 trial","volume":"36","author":"Blay","year":"2025","journal-title":"Ann Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30168-6","article-title":"Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"21","author":"Blay","year":"2020","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69446-4","article-title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial","volume":"368","author":"Demetri","year":"2006","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","article-title":"Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Demetri","year":"2013","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.21037\/jgo.2017.08.08","article-title":"Management of liver metastases from gastrointestinal stromal tumors: where do we stand","volume":"8","author":"Machairas","year":"2017","journal-title":"J Gastrointest Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.21037\/jgo-24-403","article-title":"Transcatheter arterial chemoembolization with tyrosine kinase inhibitor in the 12-year treatment of hepatic metastases from gastrointestinal stromal tumor: a case report","volume":"15","author":"Yu","year":"2024","journal-title":"J Gastrointest Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-025-02952-3","article-title":"Selective internal radiation with Y-90 resin microspheres (SIRT) for liver metastases of gastro-intestinal stromal tumors (GIST) resistant to tyrosine kinase inhibitor (TKI) therapy","volume":"132","author":"Hohenberger","year":"2025","journal-title":"Br J Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s11605-019-04278-x","article-title":"Resection combined with TKI therapy for resectable liver metastases of gastrointestinal stromal tumours: results from three national centres in China","volume":"24","author":"Chen","year":"2020","journal-title":"J Gastrointest Surg"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000001077","article-title":"The long-term efficacy of imatinib with hepatic resection or other local treatment for gastrointestinal stromal tumours liver metastases: a retrospective cohort study","volume":"110","author":"Wen","year":"2024","journal-title":"Int J Surg"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2018.10.012","article-title":"Radiofrequency ablation versus resection for resectable liver metastases of gastrointestinal stromal tumours: results from three national centres in China","volume":"43","author":"Chen","year":"2019","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v18.i42.6134","article-title":"Transcatheter arterial chemoembolization for gastrointestinal stromal tumors with liver metastases","volume":"18","author":"Cao","year":"2012","journal-title":"World J Gastroenterol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.1000-9604.2014.02.11","article-title":"A comparative study between Embosphere(\u00ae) and conventional transcatheter arterial chemoembolization for treatment of unresectable liver metastasis from GIST","volume":"26","author":"Cao","year":"2014","journal-title":"Chin J Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s11845-021-02629-9","article-title":"Irinotecan eluting beads-transarterial chemoembolization using Callispheres\u00ae microspheres is an effective and safe approach in treating unresectable colorectal cancer liver metastases","volume":"191","author":"Zhao","year":"2022","journal-title":"Ir J Med Sci"},{"key":"B22","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12957-025-03679-4","article-title":"Efficacy analysis of drug-eluting beads transcatheter arterial chemoembolization combining systemic chemotherapy and immune checkpoint inhibitors in unresectable intrahepatic cholangiocarcinoma: a multicenter retrospective cohort study based on propensity score matching","volume":"23","author":"Song","year":"2025","journal-title":"World J Surg Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2021.1943057","article-title":"Assessment of efficacy and safety by CalliSpheres versus HepaSpheres for drug-eluting bead transarterial chemoembolization in unresectable large hepatocellular carcinoma patients","volume":"28","author":"Zhao","year":"2021","journal-title":"Drug Delivery"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2353040332","article-title":"Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate","volume":"235","author":"Shankar","year":"2005","journal-title":"Radiology"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s11845-024-03611-x","article-title":"The second-line treatment of hepatocellular carcinoma with CalliSpheres drug-eluting bead transarterial chemoembolization combined with regorafenib: a safety and efficacy analysis","volume":"193","author":"Liu","year":"2024","journal-title":"Ir J Med Sci"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2021.101814","article-title":"Drug-eluting bead transarterial chemoembolization (TACE) exhibits superior efficacy and equal tolerance to conventional TACE in hepatocellular carcinoma patients with conventional TACE history","volume":"46","author":"Tang","year":"2022","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08087-4","article-title":"Tumour evolution and microenvironment interactions in 2D and 3D space","volume":"634","author":"Mo","year":"2024","journal-title":"Nature"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113436","article-title":"Exploring the eco-evolutionary dynamics of tumor subclones","volume":"12","author":"Rampias","year":"2020","journal-title":"Cancers (Bsl)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1021\/mp200458e","article-title":"Exploiting evolution to treat drug resistance: combination therapy and the double bind","volume":"9","author":"Basanta","year":"2012","journal-title":"Mol Pharm"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.00747","article-title":"Evolutionary dynamics of cancer in response to targeted combination therapy","volume":"2","author":"Bozic","year":"2013","journal-title":"Elife"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1784905\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T04:24:07Z","timestamp":1784262247000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1784905\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":30,"alternative-id":["10.3389\/fonc.2026.1784905"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1784905","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"article-number":"1784905"}}